BioMarin Pharmaceutical (BMRN) to Release Earnings on Monday

Key Points

• BioMarin Pharmaceutical (BMRN) is set to announce its Q2 2025 earnings after the market closes on August 4th, with projected earnings of $1.02 per share and $761.51 million in revenue.
• The company's stock has a market cap of $11.32 billion, with recent adjustments to price targets by multiple analysts, reflecting a range of ratings from "neutral" to "outperform."
• Insider activity revealed that CAO Erin Burkhart sold 1,786 shares at an average price of $59.31, which indicates a decline in personal ownership of the stock by 11.19%.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of $1.02 per share and revenue of $761.51 million for the quarter.

BioMarin Pharmaceutical Trading Down 1.1%

Shares of BMRN traded down $0.62 during trading hours on Thursday, reaching $58.19. 974,120 shares of the company traded hands, compared to its average volume of 1,836,579. The firm has a market cap of $11.16 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 0.80 and a beta of 0.17. The company has a current ratio of 5.52, a quick ratio of 3.49 and a debt-to-equity ratio of 0.10. The stock's fifty day moving average price is $57.09 and its 200 day moving average price is $61.90. BioMarin Pharmaceutical has a 12-month low of $52.93 and a 12-month high of $94.85.

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,786 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the sale, the chief accounting officer directly owned 14,173 shares in the company, valued at approximately $840,600.63. This represents a 11.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock worth $266,000 after buying an additional 388 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of BioMarin Pharmaceutical by 70.2% during the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company's stock worth $835,000 after purchasing an additional 4,876 shares during the last quarter. Finally, Empowered Funds LLC raised its holdings in shares of BioMarin Pharmaceutical by 207.4% during the first quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company's stock worth $850,000 after purchasing an additional 8,112 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

BMRN has been the subject of several research reports. Citigroup dropped their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group decreased their target price on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research report on Monday, May 5th. Morgan Stanley reduced their price objective on BioMarin Pharmaceutical from $97.00 to $96.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 22nd. Wall Street Zen cut BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Finally, JPMorgan Chase & Co. lifted their price objective on BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Six analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $93.74.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.